IDiyas

For the Inventor, By the Inventor

Lucknow, India

Sandeep Chandrashekharappa

USPTO Granted Patents = 17

Average Co-Inventor Count = 7.6

ph-index = 2

Forward Citations = 4(Granted Patents)


Location History:

  • Hofouf, SA (2022)
  • Lucknow, IN (2023 - 2024)
  • Raebareli, IN (2024)
  • Al-Ahsa, IN (2024)
  • Lucknow Uttar Pradesh, IN (2024)

Company Filing History:

goldMedal17 out of 3,201 
 
King Fahd University of Petroleum and Minerals
 patents

Years Active: 2022-2025

Loading Chart...
17 patents (USPTO):Explore Patents
1. 12215082 - (e)-1-(2-(4-substitutedphenyl)-2-oxoethyl)-4-((hydroxyimino)methyl)pyridinium bromides as antitubercular agents (2025-02-04),
2. 12202801 - 4-cyano-1-(2-oxo-2-(substituted phenyl) ethyl) pyridin-1-ium bromides as anti-tubercular agents (2025-01-21),
3. 12194029 - Ethyl-1-(substitutedbenzoyl)-5-methylpyrrolo[1,2-a]quinoline-3-carboxylates as anticancer agents (2025-01-14),
4. 11986476 - (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones as antitubercular agents (2024-05-21),
5. 11981674 - 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as larvicidal agents (2024-05-14),
6. 11976066 - Substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates as anti-tubercular agents (2024-05-07),
7. 11974991 - Adenosine receptor activity of methyl/ethyl 3-(substituted benzoyl)-6,8-dimethylindolizine-2-substituted-1-carboxylates (2024-05-07),
8. 11939294 - 1-(2-(substituted phenyl)-2-oxoethyl)-3,5-dimethylpyridin-1-ium bromides as antitubercular agents (2024-03-26),
9. 11938120 - Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents (2024-03-26),
10. 11926627 - Substituted 7-methyl quinoline derivatives as antitubercular agents (2024-03-12),
11. 11919900 - 1-substituted benzoyl-4-bromopyrrolo[1,2-a]quinoline-3-carboxylate derivatives as antitubercular agents (2024-03-05),
12. 11919860 - 1-2(-(substituted phenyl)-2-oxoethyl)-4-(isopropoxycarbonyl)pyridin-1-ium bromides as anti-tubercular agents (2024-03-05),
13. 11912683 - (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones as antitubercular agents (2024-02-27),
14. 11884631 - Substituted phenyl quinolin-l-ium bromide derivative as anti-tubercular agents (2024-01-30),
15. 11845746 - Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents (2023-12-19),

Title: Sandeep Chandrashekharappa: Innovator in Anti-Tubercular Compounds

Introduction

Sandeep Chandrashekharappa is a notable inventor based in Lucknow, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tubercular agents. With a total of 17 patents to his name, his work is recognized for its potential impact on treating tuberculosis.

Latest Patents

Chandrashekharappa's latest patents include innovative compounds such as (E)-1-(2-(4-substitutedphenyl)-2-oxoethyl)-4-((hydroxyimino)methyl)pyridinium bromides. These compounds are designed as antitubercular agents, specifically targeting tuberculosis treatment. Another significant patent is for 4-cyano-1-(2-oxo-2-(substituted phenyl)ethyl)pyridin-1-ium bromides, which also serves as an anti-tubercular agent. Both patents highlight his commitment to advancing medical treatments for this serious disease.

Career Highlights

Chandrashekharappa is affiliated with King Fahd University of Petroleum and Minerals, where he continues to engage in research and development. His work is characterized by a focus on creating effective solutions for combating tuberculosis, a disease that remains a global health challenge.

Collaborations

He collaborates with esteemed colleagues such as Katharigatta N Venugopala and Mohamed A Morsy. These partnerships enhance the research efforts and contribute to the innovative environment in which he works.

Conclusion

Sandeep Chandrashekharappa's contributions to the field of anti-tubercular compounds demonstrate his dedication to improving healthcare solutions. His innovative patents and collaborative efforts position him as a key figure in the fight against tuberculosis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…